Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 TrialPhilip C Schouten, Lisa Richters, Daniel J Vis, et al.Journal of the National Cancer Institute|December 29, 2020
Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation CarriersJulika Borde, Corinna Ernst, Barbara Wappenschmidt, et al.Journal of Medical Genetics|April 14, 2019
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Eric Hahnen, Stephanie Schneider, et al.Breast Cancer Research : BCR|January 26, 2018
BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancerNana Weber-Lassalle, Jan Hauke, Juliane Ramser, et al.Plos One|October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)Philipp Harter, Jan Hauke, Florian Heitz, et al.European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.International Journal of Cancer|May 18, 2022
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trialSimone N Koole, Philip C Schouten, Jan Hauke, et al.Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.JCO Precision Oncology|April 10, 2025
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study AnalysisEric Hahnen, Jan Hauke, Karen Gelmon, et al.Cancer Medicine|March 10, 2018
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian CancerJan Hauke, Judit Horvath, Eva Groß, et al.Pageof 8